GlassScriptPhysician profile
Matthew D Gold
NPI 1154338028
$9,805.37
in general payments reported to CMS, 2019-2025
40 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $894 · 2020: $979 · 2021: $1,567 · 2022: $1,557 · 2023: $1,500 · 2024: $1,876 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,775 · Education: $34.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,774.86 |
| Education | $34.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $865.90 | 2021-2025 | Nourianz |
| Abbvie INC. | $839.65 | 2021-2025 | |
| Ucb, INC. | $743.66 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Eisai INC. | $684.74 | 2020-2025 | |
| Lundbeck LLC | $613.98 | 2022-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $564.05 | 2019-2021 | |
| Pfizer INC. | $561.72 | 2023-2025 | |
| Biogen, INC. | $498.64 | 2019-2025 | Skyclarys |
| Teva Pharmaceuticals USA, INC. | $427.15 | 2019-2024 | Austedo Xr |
| Alexion Pharmaceuticals, INC. | $416.13 | 2022-2025 | Ultomiris |
| Catalyst Pharmaceuticals, INC. | $402.15 | 2020-2024 | Firdapse, Fycompa |
| Amneal Pharmaceuticals LLC | $360.25 | 2022-2025 | Rytary, Crexont, Ongentys |
| Lilly USA, LLC | $323.72 | 2022-2025 | Kisunla, Amyvid |
| Grifols USA, LLC | $291.11 | 2020-2025 | Gamunex-C |
| Celgene Corporation | $264.48 | 2020-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.